Back to "The reduction in subcutaneous fat area i..."
Strong Support
causal
Analysis v1
History

When Japanese adults with type 2 diabetes take sitagliptin plus ipragliflozin for 24 weeks, their outer fat layer shrinks, but those taking metformin gain outer fat, with a clear difference between...

72
Pro
0
Against

Evidence from Studies

Supporting (1)

72

Community contributions welcome

72

Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Randomized Controlled Trial
Human
2019 Aug

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Sign up to see full verdict

Source Study

Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Score: 72
DOI: 10.1111/dom.13750

Similar Assertions

For Japanese adults with type 2 diabetes taking sitagliptin, taking ipragliflozin for 24 weeks makes belly fat inside the body decrease more than taking metformin, with a noticeable difference in fat loss.

72
0
96%

For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin lowers insulin levels significantly more than metformin, which actually slightly raises insulin levels, with a clear difference between the two treatments.

72
0
93%

For Japanese adults with type 2 diabetes on sitagliptin, metformin reduces bad cholesterol more than ipragliflozin, which actually raises bad cholesterol levels, with a clear difference between the two treatments.

72
0
87%

For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin reduces waist size more than metformin after 24 weeks, with a noticeable difference in how much waist circumference decreases.

72
0
87%

For Japanese adults with type 2 diabetes on sitagliptin, ipragliflozin boosts good cholesterol more than metformin after 24 weeks, with a noticeable difference in how much HDL levels rise.

72
0
86%